| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $121.2M | +65.8% |
| SG&A Expense | $24.6M | +4112.9% |
| Operating Income | -$145.8M | — |
| Income Tax | $0 | — |
| Net Income | -$134.0M | -1863.9% |
| EPS (Basic) | -$4.30 | +99.9% |
| EPS (Diluted) | -$4.30 | +99.9% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $373.7M | +1111.3% |
| Short-term Investments | $51.8M | -58.5% |
| Accounts Receivable | $386K | +376.5% |
| Current Assets | $432.4M | — |
| Total Assets | $448.4M | +130.6% |
| Current Liabilities | $35.0M | — |
| Total Liabilities | $37.3M | +553.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$113.9M | — |
| Capital Expenditures | $606K | +1136.7% |
| Investing Cash Flow | $73.3M | +139.9% |
| Financing Cash Flow | $383.4M | +105.6% |
| Free Cash Flow | -$114.5M | — |
| Stockholders' Equity |
| $411.1M |
| — |